Skip to main content
Clinical Trials/NL-OMON50881
NL-OMON50881CompletedPhase 4

Effect of Bacillus Calmette-Guérin vaccination on the immunogenicity of the mRNA BNT162b2 COVID-19 vaccine in health care workers - COMBI study

Interne Geneeskunde0 sites20 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
20

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • - Age equal to or above 18 years;
  • - Written informed consent provided by the participant;
  • - Receiving BioNTech/Pfizer COVID-19 vaccine per routine care;
  • - Having received BCG-vaccination in the past 12 months OR never having
  • received BCG-vaccination.

Exclusion Criteria

  • - Legally incapacitated or unwilling to provide informed consent;
  • - History of COVID-19 infection, confirmed by a microbiological test.

Investigators

Sponsor
Interne Geneeskunde

Similar Trials

Effect of Bacillus Calmette-Guérin... | Clinical Trial